Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ).
Aurobindo Pharma Ltd announced that an inspection by the US FDA at one of its subsidiary’s warehouses in New Jersey concluded with five observations, resulting in an ‘Official Action Indicated’ (OAI) classification. Despite this, the company does not anticipate any immediate impact on its business operations and is committed to working closely with the US FDA to enhance compliance continuously.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is a prominent player in the pharmaceutical industry, primarily focusing on the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients. The company operates a significant market focus on the global scale, with a substantial presence in the USA through its subsidiary, Aurobindo Pharma USA Inc.
YTD Price Performance: -13.86%
Average Trading Volume: 18,889
Current Market Cap: 676.1B INR
See more data about AUROPHARMA stock on TipRanks’ Stock Analysis page.